<DOC>
	<DOC>NCT00141830</DOC>
	<brief_summary>The primary objective of this study is to compare the efficacy and safety of 3 dose levels of oral ERB-041 administered daily for 12 weeks versus placebo in subjects with active rheumatoid arthritis who have had a suboptimal response to therapy with stable doses of methotrexate (MTX).</brief_summary>
	<brief_title>Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Clinical diagnosis of active rheumatoid arthritis for at least 6 months and on a stable dose of methotrexate for at least 12 weeks Rheumatoid arthritis onset after 16 years of age Any significant health problem other than rheumatoid arthritis History of male or female reproductive system cancer Clinically significant laboratory abnormalities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>